Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
49 巻, 10 号
選択された号の論文の14件中1~14を表示しています
REVIEW ARTICLE
  • Toshiyuki Nagasawa, Mitsuhiko Noda, Sayaka Katagiri, Maki Takaichi, Yo ...
    2010 年 49 巻 10 号 p. 881-885
    発行日: 2010年
    公開日: 2010/05/14
    ジャーナル オープンアクセス
    Periodontitis is regarded to have a close relationship to diabetes mellitus. In Japan, some cohort studies have indicated that there is a significant positive association of obesity plus metabolic syndrome with periodontal diseases. As such, an increasing number of studies suggest a relationship between periodontitis and diabetes, most of which are epidemiologic association. In this review, we have summarized the possible evidence of a relationship between periodontitis and diabetes. To date, little evidence has been reported to indicate that diabetes and/or glucose intolerance has in fact had a significant cause-effect relationship with periodontal disease. In this regard, it is important to directly uncover the relation, i.e., to prove the effect of therapeutic approaches to periodontitis upon mitigation of glycemic control in diabetic patients, which would be a direct evidence of its causal nature. Therefore a study should be undertaken to this effect.
ORIGINAL ARTICLES
  • Kinya Okamoto, Chihiro Ishida, Yuichiro Ikebuchi, Mari Mandai, Kenichi ...
    2010 年 49 巻 10 号 p. 887-895
    発行日: 2010年
    公開日: 2010/05/14
    ジャーナル オープンアクセス
    Background and Aim Cytokines and matrix metalloproteinases (MMPs) are involved in tumor growth, invasion, and remote metastasis in various cancers. Recently, functional gene polymorphisms in these cytokines and MMPs have been found, and some reports have revealed an association between these polymorphisms and the prognosis of various cancers. In this study, we examined the relationship between the gene polymorphisms of interleukin 1 beta (IL-1b), IL-1 receptor antagonist (IL-1 RN), transforming growth factor beta 1 (TGF-b1), MMP-1, MMP-3, and MMP-9 and the prognosis of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
    Methods We enrolled 92 HCV-related HCC patients in the study, and gene polymorphisms of IL-1b -31 C/T, IL-1 RN variable number of tandem repeats (VNTR), TGF-b1 +869 C/T, MMP-1 -1,607 1G/2G, MMP-3 -1,171 5A/6A, and MMP-9 -1,562 C/T were analyzed.
    Results In HCC clinical features, TGF-b1 C carriers and MMP-3 5A carriers had significantly larger HCC diameters than TGF-b1 T and MMP-3 6A homozygotes. In HCC prognosis, IL-1b T homozygotes and MMP-3 5A carriers had a significantly poorer prognosis than IL-1b C carriers and MMP-3 6A homozygotes. Those with a combination of IL-1b T homozygosity and MMP-3 5A had synergistically poorer HCC prognosis.
    Conclusion The IL-1b -31 T allele and MMP-3 5A allele are cooperative risk factors for poor prognosis in HCC patients, suggesting that these gene polymorphisms might be potential markers for predicting the prognosis of HCC patients.
  • Yasuo Kuroki, Hiroshi Kaji, Seiji Kawano, Fumio Kanda, Yutaka Takai, M ...
    2010 年 49 巻 10 号 p. 897-902
    発行日: 2010年
    公開日: 2010/05/14
    ジャーナル オープンアクセス
    Objective Glucocorticoid (GC) causes various metabolic abnormalities; however, few prospective studies have examined the changes in glucose and lipid metabolism in newly GC-treated patients.
    Methods and Patients The present study was therefore performed to analyze markers of glucose and lipid metabolism on days 0, 3, 7, 14, 28 and at month 3 of treatment in patients starting GC therapy. Then, we analyzed the relationships between the changes in these parameters and the initial dose of prednisolone (PSL), separating groups into different regimens by the GC dose.
    Results The fasting plasma glucose (FPG) level transiently increased on day 3 of PSL administration but was restored by day 7. The immunoreactive insulin (IRI) level and HOMA-R transiently increased on day 3 and then fell, although remaining significantly higher than each basal level by day 7. A transient elevation in FPG level on day 3 was observed only in groups with a PSL dose ≥40 mg. On the other hand, total cholesterol and low-density lipoprotein cholesterol levels increased on day 3 of PSL administration and similar levels were maintained after day 7. High density-lipoprotein cholesterol levels were significantly increased on day 3; subsequently then gradually increased from days 3 to day 28. Triglyceride levels did not change during treatment. No relationship was apparent between the GC dose and the changes in each lipid parameter.
    Conclusion GC treatment induced changes in FPG, IRI, LDL-CHOL and HDL-CHOL levels from day 3 after start of GC. The dose of GC seemed to influence glucose metabolism, but not lipid metabolism.
CASE REPORTS
PICTURES IN CLINICAL MEDICINE
feedback
Top